Relmada Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    549300217EASRZ9JSF81
    ISIN
    US75955J4022 (RLMD)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Read full profile

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€60.15M
    EBIT margin
    0.0%
    Net income
    -€57.84M
    Net margin
    0.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    TRAVERSA SERGIO Chief Executive Officer +266K $0.67 +$178.20K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 124K $33.51K -40K Sell

    Earnings Calls

    Latest earnings call: August 8, 2025 (Q2 2025)

    Add to watchlist

    Notifications